Abstract
Esophageal carcinoma is the 7th most common cancer worldwide and has the 6th highest mortality rate.1 As the major subtype, esophageal squamous cell carcinoma (ESCC) is highly lethal with its patients suffering a dismal five-year survival rate of <20%.2 For locally advanced, resectable ESCCs, preoperative neoadjuvant chemoradiotherapy (neoCRT) is commonly employed. However, just like most other cancer therapies, clinical responses to neoCRT vary substantially among patients, largely owing to the lack of predictive biomarkers for patient selection.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call